Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Local delivery for gene therapy.

G L Clayman1, L Dreiling

  • 1Department of Cancer Biology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 69, Houston, TX 77030, USA.

Current Oncology Reports
|December 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic value of cathepsin L and its inhibitor headpin in oral squamous cell carcinoma.

The Journal of laryngology and otology·2012
Same author

Adenovirus-Mediated Wild-Type p53 Gene Transfer into Head and Neck Cancers.

Methods in molecular medicine·2011
Same author

Parotid gland oncocytosis: CT findings with histopathologic correlation.

AJNR. American journal of neuroradiology·2008
Same author

Human LBP-32/MGR is a repressor of the P450scc in human choriocarcinoma cell line JEG-3.

Placenta·2006
Same author

Chemokines in cancer.

Expert reviews in molecular medicine·2003
Same author

Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening.

The Journal of molecular diagnostics : JMD·2001
Same journal

Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings.

Current oncology reports·2026
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
See all related articles

Gene therapy offers a promising new treatment for head and neck cancers, especially for recurrent or metastatic cases. Clinical trials show early success with agents like RPR/INGN 201, providing hope for improved local control and enhanced treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Background:

  • Head and neck cancers present limited treatment options for recurrent or metastatic disease.
  • Gene therapy emerges as a novel therapeutic strategy for these challenging cases.
  • Gene therapy can potentially improve local tumor control and augment existing treatments.

Purpose of the Study:

  • To evaluate the potential of gene therapy as a treatment modality for head and neck cancers.
  • To explore the use of various therapeutic genes delivered via vectors for cancer treatment.
  • To assess the safety and efficacy of novel gene therapy agents in clinical settings.

Main Methods:

  • Delivery of therapeutic genes (tumor suppressor, prodrug/suicide, immune-enhancing) using specifically designed vectors.

Related Experiment Videos

  • Administration of gene therapy agents with minimal toxicity and risk of viral spread.
  • Phase I clinical trials to assess initial safety and activity of gene therapy agents.

    • Main Results:

    • Gene therapy agents can be delivered with low toxicity and minimal risk of undesirable viral spread.
    • Two gene therapy agents, RPR/INGN 201 and HLA-B7 + beta2 microglobulin, demonstrated clinical activity in phase I trials.
    • The study highlights the potential of gene therapy to enhance other treatment modalities.

    Conclusions:

    • Gene therapy is a viable and promising approach for patients with head and neck cancers.
    • The use of targeted gene delivery vectors shows potential for safe and effective cancer treatment.
    • Further clinical investigation is warranted to establish gene therapy's role in head and neck cancer management.